Navigation Links
Integrated BioPharma's Proprietary Vaccine Technology Achieves,Strong Positive Results

HILLSIDE, NJ, March 12, 2007—InB:Biotechnologies, Inc. ("BioTech"), a wholly-owned subsidiary of Integrated BioPharma, Inc. (NASDAQ: INBP), today announced strong positive results in studies of vaccines against HPV, anthrax and plague made using INBP's novel, proprietary AIPwLV™ vaccine technology. The studies were conducted by the Fraunhofer USA Center for Molecular Biotechnology (CMB), the Contract Research Organization led by Dr. Vidadi Yusibov, through which BioTech executes its vaccine-related development activities.

The results, reported in the respected peer-reviewed scientific journal Vaccine, demonstrated pre-clinical efficacy of key HPV proteins produced by the AIPwLV™ technology, which induced specific immune responses and protected against HPV challenge infection. HPV is the primary etiologic agent of cervical cancer, which represents the third leading cause of cancer-related death among women worldwide. The reported results support the possibility of producing prophylactic and therapeutic HPV vaccines using the AIPwLV™ technology.

The studies also demonstrated that other vaccine candidates made using the AIPwLV™ technology induced specific immune responses and conferred complete protection against lethal doses of anthrax and plague, two substances considered as likely bioterrorism agents.

"The AIPwLV™ technology achieves rapid, high level production of antigens, antibodies and therapeutic proteins in non-genetically modified plants utilizing a proprietary launch-vector technology," said Dr. Yusibov, the Executive Director of CMB. "It offers rapid, unparalleled scalability of vaccine production and cost efficiency, addressing the principal concerns affecting current methods of vaccine production, particularly where large scale or rapid inoculation is desired," added Dr. Yusibov.

About Integrated BioPharma, Inc. Integrated BioPharma is a unique grouping of companies presently serving the varied needs of the health care industry. Through its nutraceutical business, the Company creates, develops, manufactures and markets products worldwide. The Company’s biotechnology business uses its patented plant-based technology to produce vaccines and therapeutic antibodies. Its pharmaceutical business operates a cGMP facility for the production and sale of Paclitaxel and related drugs and provides technical services through its contract research organization. Further information is available at www.iBioPharma.com.

Statements included in this release related to Integrated BioPharma, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. Further information on potential risk factors that could affect the company's financial results can be found in the company's Reports filed with the Securities and Exchange Commission.

Contact: Jeffery Leach, VP Dina Masi, CFO Integrated BioPharma Inc 888-319-6962 d.masi@ibiopharma.com


'"/>




Related medicine technology :

1. Integrated Biopharmas Proprietary Vaccine Technology Achieves Strong Positive Results
2. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
3. Neurogen Announces Positive Results for Proprietary Insomnia Drug in Two Chronic Insomnia Clinical Trials
4. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
5. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
6. Neurogen Proprietary Insomnia Compound Data for Two Studies Presented at Associated Professional Sleep Societies Annual Meeting
7. Neurogen Proprietary Insomnia Compound Data Presented at Associated Professional Sleep Societies Annual Meeting
8. Neurogen Proprietary Insomnia Compound Data Presented at American Psychiatric Association Annual Meeting
9. Cytogen Reports Publication Validating the Utility of its Proprietary ProChart Database
10. Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
11. Helix BioMedix to Discuss Potential of Its Proprietary Peptides at the BIO International Convention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... , Oct. 12, 2017 West ... in innovative solutions for injectable drug administration, today announced ... the market opens on Thursday, October 26, 2017, and ... results and business expectations at 9:00 a.m. Eastern Time. ... or 253-336-8738 (International). The conference ID is 94093362. ...
(Date:10/11/2017)... 11, 2017  True Health, a leader in ... effort during National Breast Cancer Awareness month to ... Research recently ... that more than 10 million American women are ... BRCA1 or BRCA2 and have not had testing. These ...
(Date:10/10/2017)... 10, 2017   West Pharmaceutical Services, Inc. ... injectable drug administration, today shared the results of a ... improving the intradermal administration of polio vaccines. The study ... in May 2017 by Dr. Ondrej Mach , ... Health Organization (WHO), and recently published in the journal ...
Breaking Medicine Technology:
(Date:10/13/2017)... LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for care ... is the 90-day elimination period, when the family pays for care, is often waived, ...
(Date:10/13/2017)... ... 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun Run brought ... This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at ... towards children of all ages; it is a non-competitive, non-timed event, which is all ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Software Development, has been awarded a contract by the Center for Medicare and ... aims to accelerate the enterprise use of Agile methodologies in a consistent and ...
(Date:10/12/2017)... ... 12, 2017 , ... First Healthcare Compliance (FHC), an industry ... a range of technology and learning solutions at the 68th Annual American Healthcare ... be held October 14–18, 2017 at the Mandalay Bay Resort in Las Vegas, ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed ... consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has ... highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy ...
Breaking Medicine News(10 mins):